/DXR
DXR Stock - Daxor Corporation
Healthcare|Medical - Instruments & SuppliesNASDAQ
$12.90+4.20%
+$0.52 (+4.20%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.80
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $14.19
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DXR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.77 – $13.03
TARGET (TP)$14.83
STOP LOSS$11.87
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.01
52W High$14.15
52W Low$6.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.13M | $34.59M | $-353,357 | $-2,615,172 | $-2,806,340 |
| Gross Profit | $2.13M | $34.41M | $-1,440,430 | $-3,616,700 | $-3,492,756 |
| Gross Margin | 100.0% | 99.5% | 407.6% | 138.3% | 124.5% |
| Operating Income | $621,423 | $329,742 | $5.25M | $4.75M | $-1,730,671 |
| Net Income | $536,334 | $280,640 | $5.18M | $4.75M | $-1,705,391 |
| Net Margin | 25.2% | 0.8% | -1465.4% | -181.6% | 60.8% |
| EPS | $0.11 | $0.06 | $0.60 | $1.18 | $-0.43 |
Company Overview
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
DXRBeat Rate
33%
Last 3 quarters
Avg Surprise
-707.7%
EPS vs Estimate
Beats / Misses
1/2
Last 12 quarters
Latest EPS
$-0.34
Q2 2024
EPS Surprise History
Q2 21
+128.4%
$0.23vs$0.10
Q4 21
No data
Q2 22
No data
Q3 22
No data
Q1 23
No data
Q3 23
No data
Q2 24
No data
Q2 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 4, 2026 | — | — | — | — |
Q1 2025 | Mar 6, 2025 | — | — | — | — |
Q2 2024 | Jun 29, 2024 | — | $-0.34 | — | — |
Q2 2024 | May 16, 2024 | — | $0.72 | — | — |
Q3 2023 | Aug 28, 2023 | — | $-0.32 | — | — |
Q1 2023 | Mar 1, 2023 | — | $0.81 | — | — |
Q3 2022 | Aug 25, 2022 | — | $-0.22 | — | — |
Q2 2022 | May 15, 2022 | — | $0.78 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-0.19 | — | — |
Q2 2021 | May 15, 2021 | $0.10 | $0.23 | +128.4% | ✓ BEAT |
Q4 2020 | Nov 15, 2020 | $0.05 | $-0.85 | -1795.1% | ✗ MISS |
Q1 2020 | Feb 28, 2020 | $-0.04 | $-0.22 | -456.3% | ✗ MISS |
Q2 2019 | Jun 30, 2019 | — | $0.10 | — | — |
Q1 2019 | Mar 28, 2019 | — | $-0.06 | — | — |
Q4 2018 | Nov 14, 2018 | — | $-0.17 | — | — |
Q2 2018 | May 13, 2018 | — | $-0.17 | — | — |
Q4 2017 | Nov 14, 2017 | — | $-0.16 | — | — |
Q2 2017 | May 13, 2017 | — | $-0.05 | — | — |
Q2 2016 | Jun 30, 2016 | — | $0.43 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-1.21 | — | — |
Latest News
Daxor Announces Commercial Momentum And Clinical Validation Following HFSA Annual Scientific Meeting; Says Debut Of FDA-Cleared BVA Analyzer Signals New Era Of Data-Driven Fluid Management For Multi-Billion-Dollar Market
📈 PositiveBenzinga•Sep 30, 2025, 12:20 PM
Daxor Highlights Pilot Study Showing Fluid Assessment Errors In Sepsis, COVID-19 Patients
📈 PositiveBenzinga•Sep 4, 2025, 12:03 PM
Frequently Asked Questions about DXR
What is DXR's current stock price?
Daxor Corporation (DXR) is currently trading at $12.90 per share. The stock has moved +4.20% today.
What is the analyst price target for DXR?
No analyst price targets are currently available for this stock.
What sector is Daxor Corporation in?
Daxor Corporation operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.
What is DXR's market cap?
Daxor Corporation has a market capitalization of $0.06 billion, making it a small-cap company.
Does DXR pay dividends?
No, Daxor Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACET
Adicet Bio, Inc.
$0.49
Mkt Cap: $0.0B
ADAG
Adagene Inc.
$1.82
Mkt Cap: $0.1B
BEAT
HeartBeam, Inc.
$3.10
Mkt Cap: $0.1B
CRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
GANX
Gain Therapeutics, Inc.
$2.88
Mkt Cap: $0.1B
GEG
Great Elm Group, Inc.
$2.42
Mkt Cap: $0.1B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
NEPH
Nephros, Inc.
$5.03
Mkt Cap: $0.1B
NRXP
NRx Pharmaceuticals, Inc.
$2.37
Mkt Cap: $0.0B
XBIT
XBiotech Inc.
$2.50
Mkt Cap: $0.1B
Explore stocks similar to DXR for comparison